You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Guideline recommendations


Levetiracetam is recommended by guidelines as a first-line monotherapy in adult patients with focal epilepsy1-4

Guideline recommendations on the use of levetiracetam

National Institute for Health and Care Excellence 2020 update1

Statements are paraphrased. For further details, please refer to full document.

International League Against Epilepsy 20132

Statements are paraphrased. For further details, please refer to full document.

Scottish Intercollegiate Guidelines Network 20153

Statements are paraphrased. For further details, please refer to full document.

American Epilepsy Society 20184

Statements are paraphrased. For further details, please refer to full document.

Read more about Keppra

Abbreviations

AED: anti-epileptic drug; AES: American Epilepsy Society; FDA: Food and Drug Administration (US); ILAE: International League Against Epilepsy; NICE: National Institute for Health and Care Excellence; RCT: randomised controlled trial; Rx: prescription; SIGN: Scottish Intercollegiate Guidelines Network.

References

  1. NICE Guidelines (2020 update). Available at: https://www.nice.org.uk/guidance/cg137. Accessed April 2020.
  2. Glauser T, et al. Epilepsia 2013;54(3):551–563.
  3. SIGN 143. Diagnosis and management of epilepsy in adults: May, 2015. Available at: https://www.sign.ac.uk/sign-143-diagnosis-and-management-of-epilepsy-in-adults.html. Accessed April 2020.
  4. Kanner AM, et al. Neurology 2018;91(2):74–81.

GSK shall not be liable for any damages, claims, liabilities, costs or obligations arising from the use or misuse of information provided herein. 
For safety information on GSK products or to report an Adverse Event, please contact the toll free line 
0800 CALL GSK (0800 2255 475) or email aereporting.ng@gsk.com 
Full prescribing information is available on request on www.gskpro.com
Please note that it may take up to 10 days to process your request. If you need further assistance contact 
GSK House, 1 Industrial Avenue llupeju, Lagos or via email at customercare_ph_nigeria@gsk.com
GlaxoSmithKline Pharmaceutical Nigeria Ltd, 1 Industrial Avenue, llupeju, Lagos 234-1-271 1000 
©2020 GSK group of companies or its licensor 
Trade marks are owned by or licensed to the GSK group of companies

Keppra is a registered trademark of the GlaxoSmithKline group of companies

PM-NG-LVT-WCNT-200004 Date of preparation: November 2020.